Navigation Links
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Date:3/3/2008

compound, S110, activates an

important fetal hemoglobin biomarker in baboons, confirming the

product's ability to activate a specific silenced gene (Abstract 571).

An oral presentation by Donald Lavelle, Ph.D., of the University of

Illinois at Chicago, provided evidence that S110 increases fetal

hemoglobin and decreases DNA methylation in non-human primates and

cultured human erythroid progenitor cells (Poster 779). Finally the

prevention of cancer cell proliferation in non-clinical models, by the

Company's lead JAK2 kinase inhibitors was presented (Abstract 3560).

-- The Company announced that investigators dosed the first patient in a

multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-

targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470

in combination with several standard of care chemotherapy regimens,

including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel,

topotecan, and erlotinib. The trial is expected to enroll up to 105

patients at five study centers. The Phase 1b trial is an open label,

dose-escalation study designed to assess the safety and tolerability of

MP470 in combination with these standard of care chemotherapy regimens,

and to define the dose of MP470 to advance into Phase 2 combination

studies. Additionally, the Company will assess pharmacokinetic and

biomarker data from the study. The trial is open to chemotherapy naive

or treatment experienced patients with a variety of solid tumors

irrespective of previous lines of therapy.

Conference Call Information

SuperGen will host a conference call to discuss the results of the 2007 fourth quarter and annual financial results today at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the conference call is accessible via the investor relations section of
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... March 18 Syndication Inc., (Pink Sheets: SYNJ), Reports ... of ,Director of Technical Engineering,. The job of the ... budget development of the Company,s Pinnacle Energy Division. The ... wind turbine energy, bio-diesel fuel production, and microwave plasma ...
... 11dhTxB2 to assess aspirin effectDENVER, March 18 ... worldwide developer and marketer of diagnostic test kits, ... Test March 29 - 31 at the American ... The annual meeting will take place in Orlando, ...
... Despite the initial regulatory hiccups, the number of ... increase gradually. The patent expiry of key biopharmaceuticals ... driving the development of biosimilars. In addition, payers, ... drugs due to their safety, efficacy and affordability, ...
Cached Biology Technology:Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 2The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 4
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... TX -- Researchers at Sam Houston State University and the ... from the criminal justice system in Houston to establish protocols ... by crime labs. , "This is a problem-solving project that ... tested," said Dr. William Wells, who is leading the research ...
... 2011 -- Experts agree that obesity prevention should begin before ... conclusive data, health care providers often have trouble advising parents ... study soon to be published in The Journal of ... may be an effective way to help prevent obesity. ...
... to deliver payloads of cancer-fighting drugs to tumors in ... treatment. But scientists are still at a relatively early ... Although developing nanoparticles that work as "magic bullets" ... is still the goal, the reality is that ...
Cached Biology News:Research to target untested rape kits 2Research to target untested rape kits 3Study suggests prolonged bottle feeding increases the risk of obesity 2Hitting target in cancer fight now easier with new nanoparticle platform, UCLA scientists say 2
... antibody raised against a partial ... Immunogen: SF3B2 (NP_006833, 592 ... recombinant protein with GST tag. ... NM_006842 ...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
Biology Products: